CandlesenseCandlesense
News/Companies/CRBU

CRBU News

New Norms for Widely Used Iowa Assessments™ Provide Fresh Insights Into Post-Pandemic Student Achievement

CRBU

(NASDAQ:CRBU) Trusted by educators for nearly 90 years, the Iowa Assessments provide the most current and nationally representative normative comparison for measuring student achievement. ITASCA, Ill., Sept. 3, 2025 /PRNewswire/ -- Riverside Insights, developer of the most widely used K-12 assessments,...

September 3, 2025Education
Read more →

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

CRBU

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT.

August 25, 2025Conference
Read more →

Caribou Biosciences Q1 EPS $(0.43) Beats $(0.44) Estimate, Sales $2.35M Beat $1.75M Estimate

CRBU

May 8, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $3

CRBU

April 28, 2025
Read more →

Caribou Biosciences Discontinues GALLOP Phase 1 Trial Of CB-010 For Lupus, Reduces Workforce By ~23%, Estimates Cash payments Of $2.5M-$3.5M From Reduction In Force And Prioritization

CRBU

April 24, 2025
Read more →

Caribou Biosciences Prioritizes Oncology Pipeline, Streamlines Operations to Focus on CB-010 and CB-011 Clinical Programs, With Clinical Data Disclosures Now Planned For H2 2025

CRBU

April 24, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

CRBU

March 19, 2025
Read more →

Caribou Biosciences Expects $249.4M In Cash And Equivalents To Fund Current Operating Plan Into H2 2026

CRBU

March 10, 2025
Read more →

Caribou Biosciences Q4 2024 GAAP EPS $(0.39) Beats $(0.42) Estimate, Sales $2.08M Miss $2.11M Estimate

CRBU

March 10, 2025
Read more →

Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M

CRBU

January 13, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

CRBU

November 15, 2024
Read more →

Caribou Biosciences Q3 EPS $(0.38) Beats $(0.46) Estimate, Sales $2.02M Miss $3.10M Estimate

CRBU

November 6, 2024
Read more →

Truist Securities Maintains Buy on Caribou Biosciences, Maintains $19 Price Target

CRBU

May 16, 2024
Read more →

Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy

CRBU

May 2, 2022
Read more →